


STATUS OF THE CLAIMS

Claims 1 – 129. (canceled)

Claim 130 (currently amended). A composition comprising a benzodiazepine compound having the structure:



or its enantiomer,

wherein,

R1 is selected from the group consisting of an aliphatic group having at least 2 carbons, a substituted aliphatic group having at least 2 Carbons, an aryl group, and a substituted aryl group;

and wherein R2 and R3 is independently selected from the group consisting of hydrogen, hydroxy, alkoxy, halo, amino, lower-alkyl-substituted-amino, acetylamino, hydroxyamino, an aliphatic group having 1-8 carbons and 1-20 hydrogens, aryl, and heterocyclic;

wherein R4 is aliphatic, substituted aliphatic, aryl, substituted aryl, NH₂, or a group that participates in hydrogen bond formation;

or a pharmaceutically acceptable salt, prodrug or derivative thereof.

Claim 131. (currently amended) The compound composition of claim 130, wherein R2 is hydroxy.

Claim 132. (currently amended) The compound composition of claim 130, wherein R3 is a halogen.

Claim 133 (currently amended). The compound composition of claim 130, wherein R2 is hydroxy and R3 is a halogen.

Claim 134 (canceled).


Claim 135 (canceled).

Claim 136 (canceled).


Claim 137 (canceled).

Claim 138. (currently amended)

The compound composition of Claim 130,



wherein R4 is selected from the group consisting of



Claim 139. (currently amended)

The compound composition of Claim 130,

wherein said composition is a pharmaceutical composition.

Claim 140. (currently amended)

The compound composition of Claim 139,

further comprising a carrier.